98%
921
2 minutes
20
Pulmonary surfactant is a membranous complex that enables breathing dynamics at the respiratory surface. Extremely low values of surface tension are achieved at end-expiration thanks to a unique mixture of lipids and proteins. In particular, the hydrophobic surfactant proteins, specially the protein SP-B, are crucial for surfactant biophysical function, in order to provide the surfactant lipid matrix with the ability to form membranous multi-layered interfacial films that sustain optimal mechanical properties. To analyse the contribution of the proteins to modulate the resistance to mechanical forces of surfactant membrane-based structures, atomic force microscopy of supported lipid bilayers has been used here to determine quantitative mechanical parameters defining the effect of the presence of proteins SP-B and/or SP-C on phospholipid membranes intended to model at least part of the structures integrated into pulmonary surfactant complexes. The results show clear differences introduced by proteins in membrane thickness, lateral packing and elasticity, providing evidence supporting protein-promoted modulating of the mechanical properties of surfactant membranes. These effects are found consistent with the behaviour of two relevant native materials: whole pulmonary surfactant isolated from porcine bronchoalveolar lavages and freshly produced human pulmonary surfactant isolated from amniotic fluid, where it is transferred from the foetal lung before the respiratory air-liquid interface has been established.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.chemphyslip.2024.105464 | DOI Listing |
Pediatr Pulmonol
September 2025
Department of Neonatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India.
Background: Meconium aspiration syndrome (MAS), a common cause of respiratory failure in late preterm and term neonates, is associated with a high risk of mortality and morbidity. Amongst all the treatment modalities for severe MAS, surfactant administration has a proven role in decreasing progressive respiratory failure.
Methods: The present open-label randomised controlled trial aimed to determine the effect of early (≤ 2 h) bolus surfactant therapy as compared to standard care on the total duration of respiratory support.
Pediatr Pulmonol
September 2025
Department of Pharmacology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, Kolkata, India.
Background: Respiratory distress syndrome (RDS) is a leading cause of neonatal morbidity and mortality in low- and middle-income countries (LMICs). The feasibility and effectiveness of bovine versus porcine surfactants via less invasive surfactant administration (LISA) remain unstudied in LMICs. We compared clinical outcomes and cost-effectiveness of BLES versus poractant alfa in preterm infants with RDS managed with LISA.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Key Laboratory of Anesthesia and Intensive Care Research, Harbin, China; Department of Anesthesiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address:
Aims: Intestinal ischemia-reperfusion (II/R) injury predominantly causes acute lung injury (ALI), and in severe instances, acute respiratory distress syndrome, both associated with high mortality. Electroacupuncture (EA) excels in regulating autonomic nervous system balance and safeguarding organ function. This study delved into EA's impacts and mechanisms on II/R-induced ALI.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Marwadi University Research Center, Faculty of Pharmacy, Marwadi University, Rajkot, Gujarat, India.
Background: Cystic fibrosis (CF) is a systemic disease which primarily affects pulmonary system, but also extends to different important organs to cause multitude of associated diseases, leading to rise in rate of morbidity and mortality. The present investigation is focused on the development and optimization of SLN (Solid Lipid Nanoparticles) formulation of IVF (Ivacaftor) for effective treatment of cystic fibrosis.
Methods: IVF-SLN was formulated with the help of homogenization and ultrasonication methods by incorporating Labrasol as liquid lipid, Cetyl palmitate as solid lipid and Polysorbate 20 as the surfactant.
The ATP-binding cassette subfamily A member 3 (ABCA3) protein on the limiting membrane of lamellar bodies in alveolar type 2 (AT2) cells transports phospholipids required for pulmonary surfactant assembly. ABCA3 deficiency results from biallelic pathogenic variants in and causes progressive neonatal respiratory failure or childhood interstitial lung disease (chILD). Supportive/compassionate care or lung transplantation are the only current definitive treatments for ABCA3 deficiency and progressive respiratory failure.
View Article and Find Full Text PDF